Celon has made robust investments over the last two years to build its world-class research centre to augment its growth plans in the Global Generics segment. We are currently developing a number of generic products through a combination of internal and collaborative programs.

Our Global Generics R&D strategy focuses on the following product development areas:

  • Off-patent drugs that are difficult to develop or manufacture, or that complement or broaden our existing product lines
  • The development of Novel drug delivery technologies and the application of these technologies to proprietary drug forms.
  • Using in-house technologies to develop new products.